Journey Medical
DERM
56 hedge funds and large institutions have $46.6M invested in Journey Medical in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 7 closing their positions.
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
56% more capital invested
Capital invested by funds: $30M → $46.6M (+$16.7M)
47% more funds holding
Funds holding: 38 → 56 (+18)
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
7.84% more ownership
Funds ownership: 29.71% → 37.55% (+7.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.39M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.58M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.53M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.33M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$1.99M |
| 2 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$437K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$291K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$290K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$229K |
DERM Hedge Fund Activity: Q2 2025 in Review
56 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q2 2025, worth a combined $46.6M — up 56% from $30M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new DERM positions and 7 closed out — a net gain of 18 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $3.39M. The largest seller was Cambridge Investment Research Advisors, exiting entirely with an estimated $1.99M sold.
- 56 institutional investors held Journey Medical (DERM) as of Q2 2025, up from 38 in Q1 2025.
- Funds reported $46.6M of Journey Medical stock for Q2 2025, up 56% quarter-over-quarter.
- 25 funds opened new Journey Medical positions in Q2 2025 and 7 closed out, a net change of +18 holders.
- The largest Journey Medical buyer in Q2 2025 was BlackRock, an estimated $3.39M added.
- The largest Journey Medical seller in Q2 2025 was Cambridge Investment Research Advisors, an estimated $1.99M sold.
Based on aggregated 13F filings for Q2 2025.